Skip to main content
Top

01-05-2019 | Fluorescence in Situ Hybridization | Original Article

Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele

Authors: Yuji Nishio, Hirotaka Sakai, Yusuke Saiki, Akiko Uchida, Yu Uemura, Manabu Matsunawa, Yasushi Isobe, Masayuki Kato, Naoto Tomita, Ikuo Miura

Published in: International Journal of Hematology | Issue 5/2019

Login to get access

Abstract

Light-chain plasma cell myeloma (LC-PCM) is a PCM subtype in which only immunoglobulin light-chain is secreted. However, the absence of immunoglobulin heavy-chain (IGH) production in this condition has not been fully elucidated. To address this issue, we retrospectively analyzed patients at our center with LC-PCM and found a group who had only split signals of IGH gene derived from 14q32/IGH translocations by fluorescence in situ hybridization (FISH). Six patients were identified with only split signals of the IGH gene derived from 14q32/IGH translocations. Five of these patients were newly diagnosed, while one had IgG-λ PCM at presentation, which transformed to λ LC-PCM after treatment. The translocation partners were identified in four patients: two cases of (11;14)(q13;q32) and two cases of (4;14)(p16;q32). The development of LC-PCM appears to be explained by the application of allelic exclusion in these patients, such that 14q32/IGH translocation in one allele contributes to the pathogenesis of PCM and the subsequent loss of the other allele is responsible for the loss of IGH production. These findings suggest that a FISH pattern of IGH with “split and loss” may constitute a unique subgroup of LC-PCM.
Literature
1.
go back to reference Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.CrossRefPubMed Kyle RA, Gertz MA, Witzig TE, Lust JA, Lacy MQ, Dispenzieri A, et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc. 2003;78:21–33.CrossRefPubMed
3.
go back to reference Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–22.CrossRefPubMed Bergsagel PL, Kuehl WM. Chromosome translocations in multiple myeloma. Oncogene. 2001;20:5611–22.CrossRefPubMed
4.
go back to reference Mckenna RW, Kyle RA, Kuehl WN, Harris NL, Coupland RW, Fend F. Plasma cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, editors. WHO Classification of Tumors, Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2017. pp. 241–58. Mckenna RW, Kyle RA, Kuehl WN, Harris NL, Coupland RW, Fend F. Plasma cell neoplasm. In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H et al, editors. WHO Classification of Tumors, Tumors of Haematopoietic and Lymphoid Tissues. 4th ed. Lyon: IARC; 2017. pp. 241–58.
5.
go back to reference Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.CrossRefPubMed Bladé J, Kyle RA. Nonsecretory myeloma, immunoglobulin D myeloma, and plasma cell leukemia. Hematol Oncol Clin North Am. 1999;13:1259–72.CrossRefPubMed
6.
go back to reference Szczepański T, van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(–) subgroup of multiple myeloma. Blood. 2000;96:1087–93.PubMed Szczepański T, van’t Veer MB, Wolvers-Tettero IL, Langerak AW, van Dongen JJ. Molecular features responsible for the absence of immunoglobulin heavy chain protein synthesis in an IgH(–) subgroup of multiple myeloma. Blood. 2000;96:1087–93.PubMed
7.
go back to reference Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 2004;103:3869–75.CrossRefPubMed Magrangeas F, Cormier ML, Descamps G, Gouy N, Lodé L, Mellerin MP, et al. Light-chain only multiple myeloma is due to the absence of functional (productive) rearrangement of the IgH gene at the DNA level. Blood. 2004;103:3869–75.CrossRefPubMed
8.
go back to reference McGowan-Jordan J, Simons A, Schmid M. International system for human cytogenomic nomenclature 2016. Basel: Kargener; 2016.CrossRef McGowan-Jordan J, Simons A, Schmid M. International system for human cytogenomic nomenclature 2016. Basel: Kargener; 2016.CrossRef
9.
go back to reference Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMed Durie BG, Salmon SE. A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival. Cancer. 1975;36:842–54.CrossRefPubMed
10.
go back to reference Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMed Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Bladé J, et al. International staging system for multiple myeloma. J Clin Oncol. 2005;23:3412–20.CrossRefPubMed
11.
go back to reference Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305–10.PubMed Greipp PR, Raymond NM, Kyle RA, O’Fallon WM. Multiple myeloma: significance of plasmablastic subtype in morphological classification. Blood. 1985;65:305–10.PubMed
12.
go back to reference Burnet FM. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119–21.CrossRefPubMed Burnet FM. A modification of Jerne’s theory of antibody production using the concept of clonal selection. CA Cancer J Clin. 1976;26:119–21.CrossRefPubMed
13.
go back to reference Pernis B, Chiappino G, Kelus AS, Gell PG. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. J Exp Med. 1965;122:853–76.CrossRefPubMedPubMedCentral Pernis B, Chiappino G, Kelus AS, Gell PG. Cellular localization of immunoglobulins with different allotypic specificities in rabbit lymphoid tissues. J Exp Med. 1965;122:853–76.CrossRefPubMedPubMedCentral
15.
go back to reference Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108:2013–9.CrossRefPubMed Drayson M, Begum G, Basu S, Makkuni S, Dunn J, Barth N, et al. Effects of paraprotein heavy and light chain types and free light chain load on survival in myeloma: an analysis of patients receiving conventional-dose chemotherapy in Medical Research Council UK multiple myeloma trials. Blood. 2006;108:2013–9.CrossRefPubMed
16.
go back to reference Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1–CD49e– immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed Fujii R, Ishikawa H, Mahmoud MS, Asaoku H, Kawano MM. MPC-1CD49e immature myeloma cells include CD45+ subpopulations that can proliferate in response to IL-6 in human myelomas. Br J Haematol. 1999;105:131–40.CrossRefPubMed
17.
go back to reference Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121:3413–9.CrossRefPubMed Walker BA, Wardell CP, Johnson DC, Kaiser MF, Begum DB, Dahir NB, et al. Characterization of IGH locus breakpoints in multiple myeloma indicates a subset of translocations appear to occur in pregerminal center B cells. Blood. 2013;121:3413–9.CrossRefPubMed
18.
go back to reference Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123:3414–9.CrossRefPubMed Brioli A, Giles H, Pawlyn C, Campbell JP, Kaiser MF, Melchor L, et al. Serum free immunoglobulin light chain evaluation as a marker of impact from intraclonal heterogeneity on myeloma outcome. Blood. 2014;123:3414–9.CrossRefPubMed
19.
go back to reference Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–4.CrossRefPubMed Dawson MA, Patil S, Spencer A. Extramedullary relapse of multiple myeloma associated with a shift in secretion from intact immunoglobulin to light chains. Haematologica. 2007;92:143–4.CrossRefPubMed
20.
go back to reference Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, et al. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135:477–84.CrossRefPubMed Kühnemund A, Liebisch P, Bauchmüller K, zur Hausen A, Veelken H, Wäsch R, et al. ‘Light-chain escape-multiple myeloma’-an escape phenomenon from plateau phase: report of the largest patient series using LC-monitoring. J Cancer Res Clin Oncol. 2009;135:477–84.CrossRefPubMed
21.
go back to reference Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278–85.CrossRefPubMed Tamura H. Immunopathogenesis and immunotherapy of multiple myeloma. Int J Hematol. 2018;107:278–85.CrossRefPubMed
Metadata
Title
Light-chain plasma cell myeloma caused by 14q32/IGH translocation and loss of the other allele
Authors
Yuji Nishio
Hirotaka Sakai
Yusuke Saiki
Akiko Uchida
Yu Uemura
Manabu Matsunawa
Yasushi Isobe
Masayuki Kato
Naoto Tomita
Ikuo Miura
Publication date
01-05-2019
Publisher
Springer Japan
Published in
International Journal of Hematology / Issue 5/2019
Print ISSN: 0925-5710
Electronic ISSN: 1865-3774
DOI
https://doi.org/10.1007/s12185-019-02629-7
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine